Short Interest in Athira Pharma, Inc. (NASDAQ:ATHA) Drops By 30.7%

Athira Pharma, Inc. (NASDAQ:ATHA) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 949,500 shares, a decrease of 30.7% from the January 15th total of 1,370,000 shares. Currently, 2.7% of the company’s stock are sold short. Based on an average daily volume of 443,300 shares, the days-to-cover ratio is currently 2.1 days.

Athira Pharma Stock Up 6.4 %

NASDAQ:ATHA opened at $0.47 on Friday. Athira Pharma has a 52 week low of $0.41 and a 52 week high of $4.30. The stock has a 50 day moving average of $0.54 and a 200-day moving average of $1.01.

Institutional Investors Weigh In On Athira Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bristlecone Advisors LLC lifted its holdings in shares of Athira Pharma by 295.6% in the third quarter. Bristlecone Advisors LLC now owns 337,506 shares of the company’s stock valued at $151,000 after purchasing an additional 252,200 shares in the last quarter. GSA Capital Partners LLP lifted its stake in shares of Athira Pharma by 909.8% in the 3rd quarter. GSA Capital Partners LLP now owns 397,111 shares of the company’s stock valued at $177,000 after purchasing an additional 357,787 shares during the last quarter. Finally, BML Capital Management LLC acquired a new position in Athira Pharma during the fourth quarter worth $1,629,000. 57.12% of the stock is currently owned by institutional investors.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.